

Kindly amend claims 1, 8-11, 21, 24, and 27-29 as follows.

1. (amended) Isolated multipotent precursor cells from an olfactory epithelium of a mammal.

8. (amended) Cells differentiated from [the precursor cells of claim 1] isolated multipotent precursor cells from an olfactory epithelium of a mammal.

9. (amended) The differentiated cells of claim 8, wherein [the] said differentiated cells express neuronal markers and comprise dopaminergic neurons.

10. (amended) The differentiated cells of claim 8, selected from a group consisting of neurons, astrocytes and oligodendrocytes.

11. (amended) A pharmaceutical composition comprising isolated multipotent precursor cells from an olfactory epithelium of a mammal [The cells of claim 1], or neurons, astrocytes, or oligodendrocytes differentiated from said isolated precursor [the] cells [of claim 1], said cells in a [pharmaceutical composition for use in implant therapy, comprising a] pharmaceutically acceptable carrier, auxiliary, or excipient.

21. (amended) A kit comprising isolated multipotent precursor cells from an olfactory epithelium of a mammal [The cells of claim 1], or neurons, astrocytes, or oligodendrocytes differentiated from said isolated precursor [the] cells [of claim 1 in a kit for the treatment of a disease, disorder or abnormal physical state comprising neurodegenerative disease or neurotrauma].

24. (amended) Isolated multipotent precursor cells from a tongue of a mammal.

27. (amended) Cells differentiated from isolated multipotent precursor cells from a tongue of a mammal [the precursor cells of claim 24].

28. (amended) The differentiated cells of claim 27 [24], selected from a group consisting of neurons, astrocytes, and oligodendrocytes.

29. (amended) A kit comprising isolated multipotent precursor cells from a tongue of a mammal [The cells of claim 24], or neurons, astrocytes or oligodendrocytes differentiated from said isolated precursor [the] cells [of claim 24, in a kit for the treatment of a disease, disorder, or abnormal physical state comprising neurodegenerative disease or neurotrauma].

31. (new) The isolated precursor cells of claim 1 or 24, wherein said mammal is a postnatal mammal.

32. (new) The isolated precursor cells of claim 1 or 24, wherein said mammal is an adult mammal.

33. (new) The isolated precursor cells of claim 1 or 24, wherein said mammal is a human.

34. (new) The differentiated cells of claim 8 or 27, wherein said mammal is a postnatal mammal.

35. (new) The differentiated cells of claim 8 or 27, wherein said mammal is an adult mammal.

36. (new) The differentiated cells of claim 8 or 27, wherein said mammal is a human.

37. (new) The kit of claim 21 or 29, wherein said mammal is a postnatal mammal.

1292

38. (new) The kit of claim 21 or 29, wherein said mammal is an adult mammal.

39. (new) The kit of claim 21 or 29, wherein said mammal is a human.

40. (new) The pharmaceutical composition of claim 11, wherein said mammal is a postnatal mammal.

303

41. (new) The pharmaceutical composition of claim 11, wherein said mammal is an adult mammal.

42. (new) The pharmaceutical composition of claim 11, wherein said mammal is a human.

REMARKS

As an initial matter, Applicants thank the Examiner for granting a telephonic interview with the undersigned on May 24, 1999. As agreed upon during this interview, Applicants hereby submit a supplemental amendment.

Summary of the Invention

The invention features isolated multipotent precursor cells, and kits and